The objective of this retrospective cohort study was to estimate survival and health care costs for patients with stage IV bladder cancer. Approximately two thirds of patients were not treated with systemic chemotherapy. Patients who received chemotherapy had a longer median survival rate, fewer per-patienteper-month health care visits, and lower per-patienteper-month costs than patients not treated with systemic chemotherapy. Background: Systemic chemotherapy has long been the standard of care for advanced bladder cancer, but its cost implications are poorly understood. The objective of this analysis was to estimate survival and health care costs for patients with stage IV bladder cancer who did or did not receive chemotherapy. Patients and Methods: This was a retrospective cohort study of patients identified in the Surveillance, Epidemiology, and End ResultseMedicare database with a new primary diagnosis of stage IV bladder cancer between January 2007 and December 2011. Survival and health care visits and costs following the date of diagnosis were determined for treated and untreated patients. Costs were expressed in 2016 US dollars. Results: A total of 1215 patients were diagnosed with stage IV bladder cancer, of whom 411 (33.8%) were treated with chemotherapy and 804 (66.2%) were untreated. Median overall survival was 10 months longer for treated than for untreated patients: 13.2 (95% confidence interval, 12.3-14.1) months versus 3.2 (95% confidence interval, 3.0-3.5) months. Treated patients had fewer per-patienteper-month (PPPM) health care visits than untreated patients (7.5 vs. 10.2, P < .01) and lower total PPPM health care costs ($10,707 vs. $18,935). Overall mean total lifetime costs were greater for treated than for untreated patients ($139,893 vs. $66,829, P < .05), which was driven by an approximate 4-fold increase in life expectancy for the treated patients. Conclusion: Approximately two thirds of patients diagnosed with stage IV bladder cancer were not treated with systemic chemotherapy. Increasing the percentage of treated patients in this population could potentially extend overall survival while simultaneously lowering PPPM costs.
Introduction
The incidence rate of urinary bladder cancer in the United States is 19.8 cases per 100,000 individuals (data for 2010-2014). 1 The incidence is much higher in individuals aged 65 years than in those aged < 65 years (122 vs. 5.1 per 100,000) and in men than in women (34.9 vs. 8.4 cases per 100,000). 1 At diagnosis, the distribution of cases is 85% in situ or localized and about 4% distant (data for 2007-2013) . 1 The 5-year survival rate is approximately 5% for those diagnosed with distant disease. 1 Platinumbased combination chemotherapy has historically been the standard of care for first-line treatment of advanced bladder cancer. 2 There is, however, little information about chemotherapy treatment of patients diagnosed with advanced bladder cancer outside the clinical trial setting. The objective of this study was to describe survival rates and the costs of care after a diagnosis of advanced bladder cancer for patients who received or did not receive chemotherapy in the clinical practice setting.
Methods

Study Description
Details of the study design are provided elsewhere. 3 Briefly, this was a retrospective cohort study of patients identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Patients with a new advanced bladder cancer diagnosis on a date (the index diagnosis date) between January 1, 2007, through December 31, 2011, were followed until the earliest of the following: date of death, end of health maintenance organization (HMO) enrollment, last known date of follow-up in the SEER-Medicare database, or end of the study period (December 31, 2013) . No minimum or maximum duration of follow-up was required for the analysis. Survival, health care visits, and costs for treated and untreated patients were determined.
Study Sample
Patients were eligible for inclusion if they were aged 65 years or older; had a new primary diagnosis of stage IV bladder cancer with tumor, node, metastasis classification system staging as T4b, N0, M0, any T, N1-N3, M0, or any T, any N, M1; and had continuous enrollment in Medicare Part A and Part B with no HMO enrollment during the study period. Patients were excluded if they had a concomitant or history of a malignancy other than bladder cancer.
Treated patients were those who were treated with cisplatinbased, carboplatin-based, or noneplatinum-based cytotoxic chemotherapy regimens. Untreated patients did not receive systemic chemotherapy. Chemotherapy regimens were identified using Healthcare Common Procedures Coding System or National Drug Code numbers for specific agents categorized as carboplatin-based regimens, cisplatin-based regimens, and noneplatinum-based regimens.
Study Variables
The outcomes of interest were survival and health care visits and costs for treated and untreated patients. Health care visits and costs were determined during the follow-up period. Health care visits and costs were categorized as bladder cancer related, adverse event (AE) related, or other. Bladder cancererelated visits and costs were those with an International Classification of Diseases (ICD)-9 codes indicating bladder cancer (ICD codes 188.x, 233.7, 236.7, and 239.4) as the primary diagnosis. AE-related visits and costs were those with a primary claim for an AE of interest. AEs of interest were those occurring of severity grade 3/4, and with an incidence 5% as reported in the US prescribing information for drugs used in 1L and 2L treatment of bladder cancer. AEs of interest that required resource use, and were not only laboratory investigations (based on the Common Terminology Criteria for Adverse Events description and clinical input), were chosen for inclusion in this study. Other visits and costs were those without a primary diagnosis of bladder cancer or AEs.
Health care visits and costs were further classified by setting of care: outpatient, emergency, inpatient, skilled nursing facility, and hospice. Health care costs were also categorized by payer. Medicare Claims divides payments into 3 categories: (1) Medicare payments, (2) primary payer payments (referred to as "other payer" in this study), and (3) patient copay/deductible payments (referred to as "patient payment" in this study). The primary payer or "other payer" represents any other insurance company that the patient receives insurance from besides Medicare.
Data Analysis
This was a descriptive analysis. All analyses were stratified by patient group (treated and untreated). Patient demographic and clinical characteristics at baseline, defined as the 6-month period before the index diagnosis date, were presented as means and standard deviations for continuous variables, and numbers and percentages for categorical variables. Differences between treated and untreated patients were assessed by t tests for continuous variables and the chi-square or Fisher exact tests for categorical variables. The significance threshold was set at .05. The KaplanMeier method was utilized to evaluate time-to-event outcomes from the index diagnosis date. Survival from the index diagnosis date was expressed as a median and as a survival rate (percentage survival) at 1, 2, and 3 years. Health care visits and costs were reported as averages as well as per-patienteper-month (PPPM) values, to account for variable durations of follow-up. PPPM values were calculated as the total value divided by the patient-specific days in the follow-up period multiplied by 30. Costs are reported in 2016 US dollars.
Data were coarsened in order to conform with the Centers for Medicare and Medicaid Services Cell Size Suppression Policy, which sets the minimum threshold for the display of Centers for Medicare and Medicaid Services data. The policy specifies that no cell containing a value of 1 to 10 patients can be reported directly and no cell can be reported that allows a value of 1 to 10 to be derived from other reported cells or information.
Results
Patient Characteristics
A total of 1215 patients with advanced bladder cancer were included in this analysis, of whom 411 (33.8%) were treated with chemotherapy and 804 (66.2%) were untreated (Table 1) . Treated patients were, on average, younger than untreated patients (mean age 74.5 vs. 79.9 years, P < .01), included a greater percentage of male subjects (70.6% vs. 58.6%, P < .01), and had fewer distant metastases (61.3% vs. 68.9%, P < .01). The distributions of race, region, and setting were not significantly different between the treated and untreated patients. Figure 1 shows the Kaplan-Meier curves for survival from the index diagnosis date. Median survival from index diagnosis date for treated and untreated patients was 13.2 and 3.2 months, respectively (Table 2) . Survival rates at 1, 2, and 3 years for treated and untreated patients were 56.5% versus 12.9%, 25.6% versus 6.0%, and 15.5% versus 4.7%, respectively (P < .05 for all comparisons; Table 2 ).
Survival
Health Care Visits
Treated and untreated patients reported 7.5 and 10.2 health care visits PPPM (Table 3) . Most visits were in the outpatient setting: 6.9 and 8.8 visits PPPM for treated and untreated patients, respectively. Bladder cancererelated visits accounted for the most e910 -Clinical Genitourinary Cancer August 2018
Bladder Cancer and Chemotherapy health care visits (4.0 and 3.8 PPPM), followed by other related visits (3.1 and 4.9 PPPM) and AE-related visits (1.4 and 2.7 PPPM; Table 3 ). Over the full lifetime of patients, the mean number of health care visits per patient was 111.1 and 39.4 for treated and untreated patients, respectively (Supplemental Table 1 ).
Cancer Care Costs
The PPPM costs of cancer care during follow-up for treated and untreated patients were, respectively, $10,707 and $18,935 ( Figure 2A ). Care related to bladder cancer was the largest contributor to costs for treated and untreated patients ($4806 and $8487, respectively; Figure 2B ). AE-related costs were $1792 for treated and $3045 for untreated patients ( Figure 2C ), and other disease-related costs were $4483 for treated and $7829 for untreated patients ( Figure 2D ). When categorized by setting, treated and untreated patients incurred the greatest costs in the outpatient setting ($4600 and $3834, respectively), emergency department ($3103 and $7931), and inpatient services ($2257 and $4526; Supplemental Table 2 ).
The total lifetime costs of cancer care during follow-up for treated and untreated patients were, respectively, $139,893 and $66,829 (Supplemental Table 3 ). When categorized by payer, the distribution of costs was roughly similar between treated and untreated patients. Among treated patients, Medicare paid 85.2% of total costs, patients were responsible for 12.9% of costs, and other payers paid 1.9% of the total costs. Among untreated patients, Medicare, patient, and other payer costs were 89.4%, 8.6%, and 2.0%, respectively (data not shown).
Discussion
This study examined patients with de novo advanced bladder cancer in a database representative of the US population and found large differences in survival rates favoring chemotherapy-treated patients (median survival of 13.2 vs. 3.2 months; P < .05). Treated patients nevertheless incurred significantly lower PPPM health care costs than untreated patients. The current study also revealed that a significant proportion (approximately two thirds) of the patients in this setting did not receive any systemic therapy.
The costs of cancer care during follow-up for treated and untreated patients were $10,707 and $18,935 PPPM, respectively, corresponding to $139,893 and $66,829 in total health care costs. Emergency department and inpatient service costs were the primary drivers of cost among untreated patients and accounted for roughly two thirds of their total PPPM costs. The proportion of mean total costs related to bladder cancer, AEs, and other costs were roughly the same in the treated and untreated patients, with untreated patients having a greater proportion of AE-related costs than treated patients (10.0% vs. 4.1%). Despite Medicare paying > 80% of total costs, the cost burden for both treated and untreated patients was large. Treated patients paid $18,030 total during the course of chemotherapy, or $1272 PPPM, while untreated patients paid $5758 total, which amounted to $1502 PPPM.
The chemotherapy treatment rate reported here (34%) for the period 2007-2013 is lower than the rates reported in earlier studies. lower chemotherapy treatment rate in the current study might conceivably be related to differences in patient demographic and clinical characteristics. For example, the stage IV patients included in the Porter et al study were, on average, younger (the proportion of patients aged 75 years was 55% in Porter et al vs. 64% in the current study) and more likely to be male (72% vs. 63%). 4 In Rose et al, the median age of the patients was 69 years compared to 78 years in the current study, and fewer patients had distant metastases (36-39% vs. 61-69% in the current study). 6 Some of the demographic and clinical characteristics that were more prevalent in the stage IV population in the current study have previously been shown to be associated with a greater likelihood of not receiving chemotherapy. Rose et al 6 found that older age, female 
Kyle Flannery et al
Clinical Genitourinary Cancer August 2018 -e911 sex, a higher Charlson comorbidity index score, and presence of distant metastatic disease were associated with a lower likelihood of receiving chemotherapy, after adjusting for potential confounders in a multivariable analysis. Similarly, in the current study, untreated patients were significantly older, more likely to be female, had more distant metastases, and had a greater Charlson comorbidity index score than untreated patients (P < .01 for all comparisons). In addition, Rose et al 6 reported that black race was associated with a lower likelihood of receiving chemotherapy. In the current study, however, the racial/ethnic composition did not differ in the treated and untreated populations-and neither did the US regional and urban/rural distributions. The extent to which the differences in patient characteristics identified here (and by Rose et al 6 ) explain whether patients received chemotherapy cannot be ascertained because the SEERMedicare database does not provide a rationale for why individual patients were not treated with chemotherapy. We note several other limitations in this study. The design was descriptive rather than analytical. The differences in costs of care between patients treated or untreated with chemotherapy cannot be attributed solely to the chemotherapy treatment itself. Nor can the receipt of (3.4-6.4) Values are presented as median (95% confidence interval). 
Conclusion
Approximately two thirds of patients diagnosed with de novo stage IV bladder cancer were not treated with systemic chemotherapy. This high rate of nontreatment evident in observational data sets is understudied. The total lifetime costs of care of these patients were considerable, even though their median survival time was much lower than patients who received systemic chemotherapy. Increasing the percentage of treated patients in this population could potentially extend overall survival while simultaneously lowering PPPM costs, particularly for emergency and inpatient services. This has implications especially when considering the cost of newer immunotherapies, which should be weighed against the existing costs of chemotherapy and the monthly health care costs for untreated patients.
Clinical Practice Points
Approximately two thirds of patients diagnosed with de novo stage IV bladder cancer were not treated with systemic chemotherapy. Despite large differences in survival rates favoring chemotherapytreated patients, treated patients incurred significantly lower PPPM health care costs compared to untreated patients. Increasing the percentage of treated patients in this population of patients with de novo stage IV bladder cancer could potentially extend overall survival while simultaneously lowering PPPM costs. 
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